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Introduction: Learning is not compul-
sory... neither is survival
The problem of antimicrobial resistance is multifactorial, as
we will discuss here. In addition, current actions to prevent
antimicrobial resistance are not sufficient, and the problem is
worsening. Among the new approaches to hindering the
spread of antimicrobial resistance units (RU) are the use of
eco-evo drugs [7,51] such as COINs (conjugation inhibitors,
which prevent the transfer of resistance plasmids) [30];
blocking bacterial social behavior and communication
through interference with quorum sensing mechanisms
[19,65,67]; the old/new idea of using bacteriophages to
specifically target prevalent clones/species; fighting biofilms
[16,24]; and other, complementary approaches (for a review,
see [12]).
The ecological approach does not focus on the develop-
ment of new molecules, but rather on a novel way of think-
ing. The problem of antimicrobial resistance is not an indi-
vidual one. Each antimicrobial molecule is a potential selec-
tion determinant. Antimicrobial molecules are not restricted
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Ecology of antimicrobial resistance: humans,
animals, food and environment
Summary. Antimicrobial resistance is a major health problem. After decades of research, numerous difficulties in tackling
resistance have emerged, from the paucity of new antimicrobials to the inefficient contingency plans to reduce the use of
antimicrobials; consequently, resistance to these drugs is out of control. Today we know that bacteria from the environment
are often at the very origin of the acquired resistance determinants found in hospitals worldwide. Here we define the genetic
components that flow from the environment to pathogenic bacteria and thereby confer a quantum increase in resistance lev-
els, as resistance units (RU). Environmental bacteria as well as microbiomes from humans, animals, and food represent an
infinite reservoir of RU, which are based on genes that have had, or not, a resistance function in their original bacterial hosts.
This brief review presents our current knowledge of antimicrobial resistance and its consequences, with special focus on the
importance of an ecologic perspective of antimicrobial resistance. This discipline encompasses the study of the relationships
of entities and events in the framework of curing and preventing disease, a definition that takes into account both microbial
ecology and antimicrobial resistance. Understanding the flux of RU throughout the diverse ecosystems is crucial to assess,
prevent and eventually predict emerging scaffolds before they colonize health institutions. Collaborative horizontal research
scenarios should be envisaged and involve all actors working with humans, animals, food and the environment. [Int
Microbiol 2012; 15(3):101-109]
Keywords: ecology of antimicrobial resistance · eco-evo drugs · antibiotics · resistance units · EU antimicrobial policy ·
public health
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to the treated patients, either animals or humans, but rather
circulate throughout the whole ecosystem. Whether they are
clinically used, (e.g., hospitals, animals, wastewater) or not
(e.g., producers), antibiotics elicit selection and the spread of
RU [39]. We thus face an ecological problem, with ecology
defined in this context as the study of the relations that living
organisms have with each other and with their natural envi-
ronment. The ecology of antimicrobial resistance is in line
with conceptual terms in the framework of curing and pre-
venting disease. This relationship is of utmost conceptual
interest and operational relevance as the causal relationships,
and thus the ecology of antimicrobial resistance, properly
embrace both ecological and evolutionary theories. This dis-
cipline approaches translational research and systems biolo-
gy as unifying entities, in which the flux of resistance deter-
minants is studied, from their origin to our hospitals. 
We are now in an antimicrobial bubble, analogous to the
real estate bubble that burst in many countries around 2010.
As with all types of economic bubbles, they are generally
identified retrospectively, after they have peaked and burst.
We believe that the burst of the antimicrobial bubble is near,
given the generalized passiveness of society to alarming dis-
coveries of emerging and spreading pan-resistant pathogens
that we must set an end to. Common multidisciplinary efforts
including research on humans, animals, food and environ-
ment are not a possibility, but a need and a lesson we have to
learn… if the goal of humanity is its own survival.
A brief historical perspective 
After Alexander Fleming’s discovery of penicillin in 1928,
the use of antibiotics meant a giant leap forward in medicine.
The availability of antibiotic chemotherapy deeply changed
society by prolonging life expectancy and by allowing rapid
population growth through both a reduction in infant mortal-
ity and the ability to treat common infectious diseases such
as tuberculosis and other lung diseases, leprosy, bacterial
meningitis, and sexually transmitted diseases. Infectious dis-
eases were the major cause of hospitalization in the pre-
antibiotic era. Unfortunately, this is still the case in develop-
ing countries. The introduction of penicillin G (in 1941) and
streptomycin reduced mortality by 30 % in 1947 compared to
1938, and life expectancy world-wide extended seven years,
from 49 to 56 years, between 1955 and 1970 [11]. As an
example, in Britain, infant mortality due to congenital
syphilis dropped from 1.5 in 1910 to 0.01 cases per 1000 in
1954 due to the introduction of penicillin G. During the
decades following the discovery of penicillin, many new
molecules with bactericidal activity were found in nature
(Fig. 1), and some were even fully synthesized in vivo. Thus,
within a few years, many life-threatening diseases became
curable. It was believed, at least for some time, that infec-
tious diseases would no longer be a threat to humankind.
Hence, antibiotics were extensively used in human and vet-
erinary medicine for the treatment of many infectious dis-
eases. The observation that animal’s daily weight gain
increased with the use of low doses of antibiotics led to the
massive use of these molecules also as growth promoters
[34]. Unfortunately, soon after antibiotics where extensively
used, antibiotic-resistant (AR) bacteria emerged, proving
previous assumptions on the end of the infectious disease
threat to be wrong. Nevertheless, it was believed that bacter-
ial mutation frequencies were low enough to allow antimi-
crobial multidrug resistance to be largely ignored and meas-
ures aiming to reduce AR were accordingly not envisaged. 
Antimicrobial resistance today 
Antibiotics remain of the utmost importance, as many of the
medical interventions, from routine wound healing to cut-
ting-edge techniques such as organ transplantation or cancer
and AIDS chemotherapy, rely on the efficacy of these mole-
cules. Unfortunately, the overall picture of infectious dis-
eases and antimicrobial chemotherapy is nowadays much
more complicated and dramatically less optimistic, with mul-
tidrug resistant bacteria posing a real threat and thus a source
of major concern. In fact, bacterial resistance to antibiotics is,
currently, directly responsible for 15 times as many deaths as
AIDS every year in Europe. This increasingly perturbing
phenomenon has recently become one of the top six health
topics addressed by the European Centre for Disease
Prevention and Control. 
Bacteria have shown an enormous evolvability towards
resistance. Today, genetic mechanisms of the acquisition and
transfer of antimicrobial resistance are well known. With the
massive use of antibiotics in human and veterinary medicine,
the advantageous effect of antimicrobial resistance determi-
nants has soared. Due to selective pressure, dependent on the
extent of antibiotics usage, most current European health
policies mandate the responsible consumption of these drugs.
Consequently, the use of these compounds as growth promot-
ers in animals, a common practice in Europe until very
recently, is now forbidden in the European Union (EU).
Several studies have shown the impact of feeding antibiotics
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as growth promoters to food animals on resistance to clinical-
ly relevant antibiotics. The best-known example is the use, in
poultry and pig production, of avoparcin, a member of the
glycopeptides family and similar to the human antibiotic van-
comycin. After avoparcin was banned for use as a growth
promoter in Denmark in May 1995, the number of van-
comycin-resistant enterococci (VRE) in both animals and
humans decreased [5]. The EU decided, then, to ban its use
in the rest of the Member States in April 1997. The same phe-
nomenon was observed in several other countries including
Italy and the Netherlands [43,52,63]. The Danish experience
remains an important example of good management of
antimicrobial policy in a country [1,2]. Larger countries with
somewhat more complex structures must follow the same
path, sooner or later. 
Newer policies regarding antimicrobial use aim to
increase the awareness of the population on the need to pre-
serve the efficacy of antimicrobials. A clear example of these
policies is the European Antibiotic Awareness Day, marked
annually on the 18th of November. In accordance, drug
resistance was the topic chosen for World Health Day in 2011
(7 April 2011) by the World Health Organization (WHO).
In contrast to the increasing levels of resistance, the dis-
covery of new molecules has been in constant decline for the
last several decades and there are no encouraging perspec-
tives in the drug discovery field (Fig. 1). Unfortunately, con-
tainment seems to be the major asset in combating resistance.
Knowledge on the molecular basis of antimicrobial resist-
ance is crucial to avoid the acquisition and to hinder the
spread of resistance determinants. We now know that bacte-
ria efficiently recruit and mobilize AR genes by means of
genetic structures that exceed by far the initial expectations
concerning their genetic plasticity. Especially unexpected
was the case of integrons, genetic platforms that can capture,
stockpile, rearrange and differentially express genes, in sub-
tle coordination with bacterial stress [36,50]. Integrons,
transposons and plasmids render gene mobilization and cap-
ture so frequent that basic concepts and definitions are being
revisited. For instance, nowadays it is considered that any
given species has a core genome, with a stable content, and
an accessory genome (in some cases comprising a large por-
tion of the total DNA content), in which genetic modifica-
tions can be frequent. Consequently, we now talk about the
pan-genome of a species, defined as the totality of genes that
ANTIMICROBIAL RESISTANCE
Fig. 1. Chronology of the discovery of new antibiotic classes. The dramatic decrease in the development of new molecules is
a worrisome phenomenon. Normal type: actinomycete bacteria products. Blue: fungal products. Red: non-actinomycete bac-
teria products. (From [38], by permission of Oxford University Press, Inc.)
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have been found in members of a given species. In the pan-
genomes of clinically important bacteria, antimicrobial
resistance determinants are now prevalent.
The mechanisms 
Mechanisms of antimicrobial resistance can be grouped in
seven classes: 
1. Drug inactivation. Bacteria produce enzymes that
can modify the drug, rendering it inactive or less active at
therapeutic concentrations. These enzymes are efficient and,
therefore, common among clinical isolates. The chemical
modification induced in the antibiotic molecule can vary.
Some enzymes bind radicals to the antibiotic, as is the case
of chloramphenicol acetyl-transferases (CAT), aminoglyco-
side adenylases and phosphotransferases; others, like β-lacta-
mases, hydrolyze the antibiotic molecule. Although the genes
coding for those enzymes are frequently harbored in plas-
mids, it has been speculated that these genes originate from
the chromosomes of yet unknown bacteria, in which they
probably accomplish physiological functions. Once mobi-
lized and overexpressed, these genes become resistance
determinants. Supportive evidence for this hypothesis is the
β-lactamase encoded by ampC, a resistance gene common in
clinical isolates and identified in the chromosomes of two
strains of β-lactam-susceptible Citrobacter freundii isolated
during the 1920s [8], i.e. long before the clinical use of
antibiotics.
2. Target modification. Antibiotic activity is depend-
ent on the high affinity these molecules have for structures
that are necessary for bacterial metabolism and integrity.
Some of the bacterial targets of antibiotics can undergo struc-
tural modifications and still accomplish their function. When
these modifications result in a decrease in the affinity of the
drug, this process becomes a resistance mechanism. Some of
these modifications are pre-transcriptional, with mutations in
the genes encoding the targets that will ultimately give rise to
GONZALEZ-ZORN, ESCUDERO
Fig. 2. Schematic representation of the most common resistance mechanisms. 1: Entrance of the antibiotic through porins. 2: Binding to the target. A: Loss
of porins. B: Antibiotic inactivating enzymes by modification (B1) or by hydrolysis (B2). C: Enhanced efflux. D: Pre-transcriptional modification of the tar-
get. E: Post-translational modification of the target. (i) Bacterial chromosome bearing the gene encoding the target. (ii) Resistance plasmid bearing genes
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amino acid modifications in the protein. Others are post-
translational, when modifications in the already-synthesized
target are at the basis of the decrease in affinity. A good
example of pre-transcriptional modification is the main
mechanism of resistance against fluoroquinolones (FQs), in
which mutations in gyrA and parC (genes coding for a sub-
unit of the FQ targets) entrain amino acid substitutions
responsible for a decrease in the affinity of the antibiotic for
the target, while preserving the protein’s activity [28]. A
more recent example of post-translational modification of the
target is the group of 16S rRNA methylases, discussed below.
These enzymes confer high levels of resistance to aminogly-
cosides by simply adding a methyl group to the ribosome
[32,37]. The resulting interference with antibiotic binding is
dramatic, as resistance can increase up to 100-fold.
3. Reduction in the intracellular concentration
of the antibiotic. Antibiotic molecules must generally
reach the cytoplasm to exert their function, because many tar-
gets of antibiotics are intracellular. Thus, preventing the
accumulation of these compounds in the cytoplasm leads to
reduced susceptibility. This can be mediated either by the
loss of porins in the cell wall, therefore limiting the entrance
of molecules into the cell, or by the enhanced efflux of mol-
ecules. Efflux is mediated by proteins that span the wall and
act as pumps, extruding compounds from the cytoplasm to
the extracellular environment. Overexpression of these mol-
ecules or changes in their substrate specificity can lead to
antimicrobial resistance [29,33,54]. This mechanism is espe-
cially worrisome due to the ubiquitous presence of efflux
pumps in living organisms, and because efflux pumps often
show a multidrug spectrum of substrates [45]. 
4. Reduced target expression. A decrease in the
availability of the topoisomerase IV has been observed to be
at the origin of low-level FQ resistance in Staphylococcus
aureus [40]. Antibiotic targets are, by definition, molecules
that are essential for bacterial survival. Thus, this is an exam-
ple of plasticity in the rise of resistance. Another example of
extreme reduction in target expression is that of glycopeptide
resistance mediated by the van family of operons. These
resistance operons allow abolishing the synthesis of gly-
copeptide targets (peptidoglycan precursors ending in D-Ala),
and their replacement for D-Lac or D-Ser-ending variants
showing a decreased affinity for the antibiotics [20].
5. Target protection. This phenomenon is observed for
Qnr proteins, which mimic DNA structure and thus interfere
allosterically with the binding of FQs to their targets, result-
ing in rising FQ resistance levels [62]. These determinants
are currently spreading among clinically relevant enterobac-
teria but they have also been found in gram-positive bacteria
such as enterococci [4].
6. Antibiotic sequestering. In this resistance mecha-
nism, the molecules are not inactivated but instead are simply
hampered or trapped in other structures. Examples of this
mechanism are bleomycin resistance [27] and the cell wall
thickening observed in glycopeptide-intermediate Staphy-
lococcus aureus (GISA) [21]. 
7. Defective antimicrobial activation. Some antibiotics
are pro-drugs and need to be activated by bacterial or host
enzymes in order to become bactericidal. Resistance to these
agents can therefore be mediated by the loss of the corresponding
enzyme, its function, or its affinity for the antibiotic [58].
Antimicrobial resistance is ancient 
As mentioned before, antimicrobial resistance is not a novel
phenomenon. Antimicrobial resistance genes dating back to
30,000 years ago have been found in highly diverse collec-
tions of genes encoding resistance to β-lactam, tetracycline
and glycopeptide antibiotics [22]. The origin of these genes
are often antibiotic producers or bacteria cohabiting with pro-
ducers, although not always, as discussed later. Most antimi-
crobials used to date come from bacteria or fungi inhabiting
different ecological niches in nature [46]. In the case of bac-
teria, the microorganisms have to avoid their own suicide as
a consequence of producing high amounts of antibiotics.
These resistance determinants have been selected throughout
thousands of generations and are thus very effective in their
hosts. Resistance elements can then be transferred to bacteria
residing in the same niche through horizontal gene transfer
(HGT) events, mainly based on conjugation, transformation
and transduction. In new genetic backgrounds, these genes
are not always successful; rather, selection depends on sever-
al factors, which can be explained with the four Ps [7]: (i)
Penetration refers to the ability of a genetic element from a
particular system to enter and be present in other systems.
Examples are RU that confer high-level resistance to antibi-
otics in antibiotic producers, which ultimately provide the
same function in pathogenic bacteria. (ii) Promiscuity is the
ability to exchange genetic sequences with other members of
the ecosystem. (iii) Plasticity is the tolerated variability in the
ANTIMICROBIAL RESISTANCE
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genetic sequences, ranging from changes in the sequence of
nucleotides in a gene to changes in the order of genes in a
genome (synteny), in the modular structure of genetic
regions (modularity), or in the modulation of their expres-
sion. (iv) Persistence is the ability of each resistance unit to
“construct a niche” in a specific context so that permanent
links with its surrounding environment (including the genetic
context) are established, allowing long-term coexistence or
fixation of the sequence or element in the system.
Thus, effective antimicrobial resistance genes from
antibiotic producers are not per se efficient resistance deter-
minants in pathogenic bacteria. However, the reverse can be
stated: all acquired resistance determinants in our hospitals
have an origin in the environment.
Ecological dimensions 
Ecology is classically defined as the study of the relations
that living organisms have to one another and to their physi-
cal surroundings. Expressed more abstractly, ecology can be
seen as the study of the relations and interactions of any set
of actors in a given framework, both among themselves and
with the framework as a whole. Antimicrobial resistance has
not one, but several ecological dimensions. 
The macroscopic dimension. Antimicrobial resist-
ance in hospitals and in the community is a multifactorial
problem. From a public health point of view, the concern that
bacteria will become resistant during antibiotic treatment is
negligible compared to the impact of the dissemination of
resistant bacteria in the environment. Our current lifestyle
allows for are extremely frequent and essentially borderless
interactions with other humans, with resistant microbes being
transmitted and transported between virtually any two points
of the globe. As mentioned above, in this scenario animals
can have a major impact on the origin of resistant clones as
well as acting as reservoirs thereof. Transmission from ani-
mals to humans can occur through direct contact with living
animals, but also through food obtained from animals colo-
nized with resistant bacteria. Food-borne resistance also
allows, through imports and exports, for an international cir-
culation of resistance genes. Finally, some abiotic factors in
this framework are also important in preventing the emer-
gence of resistance. Antibiotics are currently being accumu-
lated in the environment and some molecules such as FQs
have long half-lives. Indeed, the delivery of antibiotics to the
environment has to be minimized in order to decrease selec-
tive pressure and to limit the occurrence of new mechanisms
of resistance [3]. Measures aiming to do so can range from
the obvious need to control disposal of the molecules during
their industrial production, to the lesser one of preventing
waste materials from patients undergoing chemotherapy
from reaching the environment. 
The microscopic dimension. Antimicrobial resistant
clones live together with many other bacteria in extremely
complex habitats, such as the gut, skin, and mucosae of ani-
mals and humans, or natural environments. In these settings,
communication, cooperation and competition take place con-
tinuously among billions of members belonging to hundreds
of different species [35,53]. The microscopic dimension is
currently being redefined through the use of massive
sequencing technology, which has revealed an enormous
level of complexity. The number of ecosystems is virtually
infinite, and bacteria are not restricted to a given niche, but
can move from one to another. This circulation of bacteria
between humans and the environment provides a link
between the environmental genetic pool and the microbiome
in such a way that selective pressure in either system will
eventually have an impact on public health. 
DNA (including resistance markers) can be acquired from
the environment through transformation, or from other mem-
bers of the community through conjugation or transduction.
Consequently, the success of resistance versus susceptibility
(and therefore the probability of dissemination of resistant
clones) depends mainly on one factor: fitness. In a given sce-
nario, fitter bacteria overgrow other populations and prevail
[66]. It is generally assumed that the acquisition of resistance
confers a fitness advantage during antibiotic treatment but
that it entails a fitness cost in the absence of antibiotics [60].
Hence, resistant clones should be cleared from a population
if the antibiotic is discontinued [44,61]. Nevertheless, several
phenomena, such as the accumulation of compensatory
mutations in other loci, can counteract this fitness loss [10].
Also, the co-occurrence of two or more resistant phenotypes
in a cell (multiresistance) can enable a co-selection phenom-
enon. In a clinical environment with recurrent antibiotic
treatments, co-selection can compensate the fitness cost of a
gene in the absence of the antibiotic to which it confers
resistance. The selective advantage of the resistant strain har-
boring these mechanisms enables it to proliferate and spread,
ultimately overgrowing the susceptible strains and stabilizing
the determinants within the population. In addition, several
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mechanisms are so efficient that they induce little if any fit-
ness cost, proving that the acquisition of resistance determi-
nants can be a win-win situation [31]. Of all the potential ele-
ments that are found in environmental and human resistomes,
only the fittest prevail in hospitals.
The molecular dimension. Horizontal gene transfer is
an evolutionary highway for bacteria. Therefore, the success
of an antimicrobial resistance determinant at the molecular
level depends mainly on its mobilization capacities. Plasmids
currently play a major role in the mobilization of resistance
genes between cells. Intrinsic features of plasmids, such as
their host range, their incompatibility group [15], or whether
they are conjugative or can be mobilized [59], directly influ-
ence the spread of the resistance marker they harbor. Other
factors, such as the linking of different resistance genes with-
in a plasmid, also influence the success of a given resistance
gene as it allows for an undesired co-selection phenomenon
that increases its persistence [14]. The transfer of resistance
markers between replicons can be accomplished by trans-
posons, allowing for the circulation of resistance genes
among plasmids or between plasmids and chromosomes.
Also, gene recruitment platforms such as integrons help to
acquire new genes and are themselves associated with trans-
posable elements. Nowadays, it is commonplace to find in
hospitals resistant clones bearing several antimicrobial resist-
ance genes within a class 1 integron, associated with a Tn402
transposon, embedded in a Tn21 transposon [13] and borne
by a conjugative plasmid. Furthermore, upon antibiotic treat-
ment, the bacterial SOS-response (triggered by many differ-
ent antibiotics) [6] activates an integrase that reshuffles the
integron content until it acquires a fitter conformation [9].
Altogether it is clear that the ecology of antimicrobial
resistance has no political borders and that the need for a
common international effort involving policy makers,
researchers and health professionals from all fields is critically
urgent.
Antimicrobials: the driving force from
the environment to our hospitals 
Today we know that antimicrobial resistance genes in hospi-
tals have an origin in nature. This does not mean that the role
of the RU was always related to antimicrobial resistance [47].
For instance, resistance genes like the FQ resistance determi-
nants qnr have been found in environmental bacteria such as
Aeromonas spp., residing in geographically unrelated water
bodies [17,55]. Qnr proteins confer resistance to FQs,
although the latter are fully synthetic antimicrobial molecules
that were not present in nature before the mid 1950s. These
resistance genes are found in the chromosome of gram-posi-
tive and gram-negative bacteria [41,42,57], with marine bac-
teria thought to be the origin of clinically relevant alleles
[18]. As late as 1998, Martínez-Martinez and co-workers
identified the first transferable FQ-resistance determinant
[49], which is now very prevalent in pathogenic bacteria
worldwide. Although the role of qnr genes in nature is not
related to antimicrobial resistance, we know that these genes
have been present in environmental bacteria for thousands, if
not millions of years. Selection through the use of FQs has
been the driving force that has brought these elements to hos-
pitals.
In some other cases, the function of the RU in nature is
ANTIMICROBIAL RESISTANCE
Fig. 3. Resistance through 16S rRNA methylation. A single methyl group at
position N7 of nucelotide G1405 in the 16S rRNA (red circle) is enough to
hinder binding of 4–6-disubstituted aminoglycosides to the ribosome, con-
ferring high-level resistance to these drugs. This resistance mechanism is
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retained by its diverse bacterial hosts in hospitals. This is the
case of the 16S rRNA methyltransferases, which confer high-
level aminoglycoside resistance. These enzymes specifically
methylate a single nucleotide of the 16S rRNA ribosome,
G1405. With a methyl group in this position, 4–6-disubstituted
aminoglycosides such as tobramycin, amikacin or gentamicin,
the clinically most commonly used molecules of this family, are
sterically hindered and thus unable to bind to their site of action,
the aminoglycoside-binding pocket (Fig. 3). 
Aminoglycoside-producing bacteria have developed
methods to ensure their own protection. For example, to pro-
tect itself from the gentamicin it produces, Micromonospora
purpurea adds a methyl-group to the G1405 position of its
own ribosome, resulting in high-level resistance to the antibi-
otic. Enzymes of the same family, such as ArmA and RmtA-
F have been identified mainly in enterobacteria [23,25,26,32,
64,68]. Some of these enzymes have been shown to likewise
modify nucleotide G1405 by the addition of a methyl group,
again conferring high-level resistance to aminoglycosides
and hence rendering these antibiotics useless against bacteria
that have acquired these genes. The gene encoding RmtC has
further integrated into the chromosome of Salmonella enter-
ica serovar Virchow [37] without affecting the fitness of the
host bacterium. Thus, acquired genetic elements from nature
can retain their function and encounter adaptive mutations
that enable them to preserve their original environmental
function in pathogenic bacteria from hospitals [56].
Furthermore, these genes have been identified in animal iso-
lates as well as in isolates from food, proving, again, that the
path from the environment to the hospital involves not only
humans and environmental bacteria but also animals and
food products. 
Antimicrobial resistance is an increasingly dangerous phe-
nomenon. Thus, efficient collaboration between all actors
involved is crucial to identify, assess and predict RU before they
colonize our hospitals [48]. In this sense, the ecology of antimi-
crobial resistance is an emerging discipline that is contributing
new models and solutions to combat this uncontrolled pandemic.
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SEM Biennial Prize
The Spanish Society for Microbiology (SEM) Biennial Prize dates back to 1983, when the SEM decided that a lecture should
be given by a young researcher at each SEM National Congress. The nominees are selected from among the SEM member-
ship; they must be under 40 years of age, and carrying out research of excellence in a field of microbiology. The following
researchers have been awarded the SEM Biennial Prize (the centers indicated are those where the scientists worked when they
received the prize).
